Overall considered, HER2-low breast cancer is emerging as a distinct entity among the heterogenous population of HER2-negative tumors, and the proportion of breast cancer patients exhibiting HER2-low expression is not negligible, accounting for more than a half of all HER2-negative breast cancers13,14. This evidence concerns the gene ERBB2 and breast carcinoma.